Regenxbio INC Form 4 insider transactions

Steve Pakola, Chief Medical Officer of REGENXBIO Inc., reported a transaction in 7,468 shares of common stock on August 1, 2026.

Patrick J. Christmas, Chief Strategy & Legal Officer of REGENXBIO Inc., reported a transaction in 4,699 shares of common stock on August 1, 2026.

REGENXBIO Inc. executive Curran Simpson reports transactions related to the Employee Stock Purchase Plan and tax withholdings for restricted stock units.

REGENXBIO Chief Medical Officer Steve Pakola executed a Rule 10b5-1 plan transaction involving the acquisition and disposition of company stock.

REGENXBIO Inc. Chief Medical Officer Steve Pakola reported transactions involving the sale of common stock and the exercise of stock options, executed under a pre-arranged trading plan.

Director Daniel Tasse was granted 9,807 restricted stock units and 46,600 stock options as part of annual equity compensation.

Director David C. Stump was granted 9,807 restricted stock units and 46,600 stock options by REGENXBIO Inc.

Director Jennifer Zachary was granted 9,807 restricted stock units and 46,600 stock options by REGENXBIO Inc.

REGENXBIO Inc. Director Kenneth T. Mills reported transactions involving common stock and stock options on May 29, 2026.

Regenxbio Inc. reports that Director George V. Migausky acquired 9,807 shares of common stock and was granted options for 46,600 shares.

RegenxBio Director Argeris N. Karabelas acquired shares and stock options, indicating continued investment and commitment to the company.

REGENXBIO Inc. reports that Director Alexandra Glucksmann acquired 9,807 shares of common stock and was granted options for 46,600 shares.

Director Allan M. Fox of REGENXBIO Inc. reported transactions involving common stock and stock options, including the acquisition of shares underlying a restricted stock unit award.

REGENXBIO Inc. reports that Director Jean Bennett acquired 9,807 shares of common stock and was granted options for 46,600 shares.

REGENXBIO Chief Medical Officer Steve Pakola sold 15,309 shares of common stock at a weighted average price of $11.02.

REGENXBIO's Chief Medical Officer, Steve Pakola, sold 5,124 shares of common stock for $10.35 per share under a Rule 10b5-1 trading plan.

REGENXBIO's Chief Strategy & Legal Officer, Patrick J. Christmas, reported a disposition of 4,700 common shares to cover tax obligations related to vested restricted stock units.

REGENXBIO's Chief Medical Officer, Steve Pakola, disposed of 5,267 shares of common stock to cover tax obligations related to RSU vesting.

REGENXBIO Director Kenneth T. Mills exercised 225,000 stock options and simultaneously disposed of shares to cover the exercise price and taxes.

REGENXBIO's Chief Medical Officer, Steve Pakola, acquired 65,847 shares of common stock and 35,402 stock options on January 6, 2026.

REGENXBIO Inc.'s Chief Technology Officer, Craig Malzahn, was granted 65,847 restricted stock units and 35,402 stock options on January 6, 2026.

REGENXBIO Inc.'s CEO, Curran Simpson, was granted 144,864 restricted stock units and 233,651 stock options, vesting over several years.

REGENXBIO's Chief Strategy & Legal Officer, Patrick J. Christmas, received significant equity awards, including restricted stock units and stock options, on January 6, 2026.

REGENXBIO Inc.'s Chief Financial Officer, Mitchell Chan, was granted 73,749 shares of common stock through restricted stock units and 39,650 stock options on January 6, 2026.

REGENXBIO Inc.'s CEO, Curran Simpson, disposed of 18,559 common shares to cover tax liabilities related to RSU vesting.

REGENXBIO's Chief Technology Officer, Craig Malzahn, disposed of 1,238 common shares to cover tax liabilities from vested restricted stock units.

REGENXBIO's Chief Strategy & Legal Officer, Patrick J. Christmas, disposed of 9,793 common shares to cover tax liabilities related to RSU vesting.

REGENXBIO's Chief Medical Officer, Steve Pakola, disposed of 18,247 common shares to cover tax liabilities related to restricted stock unit vesting.

REGENXBIO Inc.'s CEO, Curran Simpson, sold 20,811 shares of common stock for $12.62 per share under a pre-arranged 10b5-1 trading plan.

REGENXBIO Inc. CEO Curran Simpson sold 7,624 shares of common stock at a weighted average price of $10.03 per share under a Rule 10b5-1 trading plan.